Biotechnology Today Everest Medicines announced the approval of its New Drug Application (NDA) for Trodelvy (sacituzumab govitecan) from China’s National Medical Products Administration (NMPA) to treat adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. 10 June 2022